9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...
22 February 2024 - Joint media release with Health New Zealand. ...
18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...
18 January 2024 - Draft guidance for public consultation has been published by NICE. ...
11 January 2024 - A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be ...
20 December 2023 - A vaccine to combat the newer strains of COVID-19 has been approved and will be available ...
6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...
20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...
18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...
16 August 2023 - PHARMAC is interested to hear from pharmaceutical suppliers who manufacture vaccines that protect against COVID-19 and ...
1 August 2023 - PHARMAC is consulting on changes to the access criteria for all COVID-19 anti-viral treatments to include ...
27 July 2023 - PHARMAC has confirmed today that molnupiravir will remain available as a treatment to protect against infection ...
14 June 2023 - NICE has published final evidence-based recommendations on the use of tixagevimab and cilgavimab (Evusheld) for the ...
4 May 2023 - NICE is conducting a partial rapid review of TA878. ...
4 April 2023 - PHARMAC are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments. ...